drugset / Trial / NCT03953209
Spironolactone for the Treatment of Melasma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to prospectively gather data on the efficacy and tolerability of spironolactone to treat refractory melasma and to compare treatment response of randomized 50 mg, 100mg, and 200mg per day dosing.
Timeline
- Start
- 2020-03-05
- Primary completion
- 2021-01-01
- Completion
- 2021-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Spironolactone | Small molecule | 50 mg | Oral |
| Subject | Spironolactone | Small molecule | 100 mg | Oral |
| Subject | Spironolactone | Small molecule | 200 mg | Oral |